UK-Japan FTA: Banishing UK Pharma’s Brexit Blues
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as…
Address: Department for Business, Innovation & Skills, 1 Victoria Street, London SW1H 0ET, United Kingdom
Tel: +44 (0)20 7215 5000
Web: https://www.gov.uk/government/organisations/department-for-business-innovation-skills
The Department for Business, Innovation and Skills (BIS) is building a dynamic and competitive UK economy by: creating the conditions for business success; promoting innovation, enterprise and science; and giving everyone the skills and opportunities to succeed. To achieve this it will foster world-class universities and promote an open global economy. BIS – Investing in our future
The Department for Business, Innovation and Skills (BIS) has an important role at the heart of government as the ‘department for growth’.
That’s why BIS is leading work across government to develop a more balanced and sustainable model for growth. We are building on the Strategy for Sustainable Growth, published in July, with a view to publishing a White Paper in the autumn.
British business can’t prosper while the risk of a debt crisis hangs over the economy. Striking the right balance between making savings and promoting sustainable growth is crucial. This is not just about cuts, but about creating a stable environment that enables businesses to invest and grow with confidence.
We aim to create an enterprise culture where everyone with talent is inspired to turn ideas into successful enterprises and get rid of unnecessary barriers that can stifle growth.
There are three key ways BIS is contributing:
x promoting business and innovation;
x creating a highly-skilled workforce and;
x promoting free and open markets.
The Government, led by BIS, wants to rebalance the economy. This means moving away from an economy reliant on debt to a sustainable one that is greener and more technologically advanced. And it means creating opportunities which are spread more across the regions, and through those sectors where the UK is strong and can add real value.
In a world where there is less money, the role of the state needs to change to get a smarter balance of public and private investment in the economy. We will refocus public spending on those areas where it has the greatest impact on growth and make sure that wider Government policy protects and supports the business environment.
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial asset on the market, a strong pipeline of development assets and a…
Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
See our Cookie Privacy Policy Here
